Dr. Jonathan Lu
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 222
Licensed in Texas since 2019, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license S1170 (first issued 2019; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist the Woodlands Hospital The Woodlands, TX
- HCA Houston Healthcare Tomball Tomball, TX
- Huntsville Memorial Hospital Huntsville, TX
- Aspire Hospital Conroe, TX
Medical groups
- David P Ellent PLLC (58 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 222
- Services billed
- 89,276
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 27,030 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 794 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 443 | 155 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 306 | 35 |
| Administration of chemotherapy into vein, 1 hour or less | 115 | 16 |
| Injection, diphenhydramine hcl, up to 50 mg | 96 | 33 |
| Administration of additional new drug or substance into vein, 1 hour or less | 65 | 11 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 60 | 24 |
| Administration of chemotherapy into vein, each additional hour | 55 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Tomball, TX | 74 |
| Anastrozole Other prescribers in Tomball, TX | 66 |
| Xtandi (enzalutamide) | 63 |
| Xgeva (denosumab) Other prescribers in Tomball, TX | 61 |
| Abiraterone Acetate | 56 |
| Oxycodone Hcl Other prescribers in Tomball, TX | 53 |
| Ondansetron Odt (ondansetron) Other prescribers in Tomball, TX | 51 |
| Dexamethasone Other prescribers in Tomball, TX | 48 |
| Eliquis (apixaban) Other prescribers in Tomball, TX | 46 |
| Lupron Depot (leuprolide acetate) | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 50 companies reported 232 payments worth $4,872 in total to this clinician.
| Janssen Biotech, Inc. | $522 |
|---|---|
| Pfizer Inc. | $443 |
| AstraZeneca Pharmaceuticals LP | $298 |
| Eisai Inc. | $215 |
| Tempus Ai, Inc | $212 |
| E.r. Squibb & Sons, L.l.c. | $186 |
| Bayer HealthCare Pharmaceuticals Inc. | $180 |
| Merck Sharp & Dohme LLC | $180 |
| Food and Beverage | $4,772 |
|---|---|
| Education | $99.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 22, 2025 | Education ERLEADA · Oncology · in-kind | $99.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $541,960 in research payments for these studies, mostly to the institutions running them.
- A phase 1B evaluating safety, efficacy, pk and pd of glofitamab plus gem-ox in rem ptswith r/r dlbcl
Genentech, Inc. - Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC - A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS …
Genentech, Inc. - An openlabel randomized controlled phase 3 study of sigvotatug vedotin in combination with pembrolizumab compared with pembrolizumab monotherapy as firstline treatment in participants with PDL1 high 50 of tumor cells …
Pfizer Inc. - A Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistimab Alone versus Lenalidomide Alone in Participants with newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Ce…
National Marrow Donor Program - Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie Inc. · Active, not recruiting · NCT03821935 - Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Active, not recruiting · NCT06236438 - Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len
Genentech, Inc. - A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.